Cancer Chemotherapy and Pharmacology

, Volume 60, Issue 3, pp 351–356 | Cite as

Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer

  • Peng-Chan Lin
  • Wei-Shone Chen
  • Ta-Chung Chao
  • Shung-Haur Yang
  • Chui-Mei Tiu
  • Jin-Hwang LiuEmail author
Original Article



Metronomic chemotherapy, at a minimally toxic dose and with a frequent schedule, is a potentially novel approach to the control of advanced cancer disease via a different mechanism from maximum tolerable doses chemotherapy. Taking advantage of the potential effectiveness of metronomic therapy, tegafur/uracil (UFT) was incorporated into an oxaliplation/infusioanl fluouracil (5-FU)/leucovorin (LV) protocol in this study. The primary endpoints were response rate, time to progression (TTP) and safety profile in 5-FU-pretreated metastatic colorectal cancers (CRCs).

Patients and methods

Twenty-eight patients with metastatic CRCs resistant or refractory to 5-FU/LV were enrolled. Chemotherapy was administrated every 2 weeks sequentially with 2-h infusion of oxaliplatin (85 mg/m2) and LV (200 mg/m2), intravenous bolus 5-FU (400 mg/m2), 22-h infusion of 5-FU (600 mg/m2) on day 1 and then followed by 10-day daily oral UFT (200 mg/m2)/LV (30 mg/m2).


Partial response was seen in ten (35.7%) patients. The median TTP was 5.2 (95% CI: 4.16–6.31) months and the median overall survival was 13.4 (95% CI: 6.39–20.5) months. No grade 3 toxicities above 5% according to National Cancer Institute-Common Toxicity Criteria (NCI-CTC) occurred except sensory neuropathy (10.7%). No grade 4 toxicity, treatment-related mortality or hand–foot syndrome was found.


This study protocol with favorable toxicity profile is thus promisingly effective against 5-FU-pretreated metastatic CRCs. Given the present experience, an evaluation of the regimen as front-line treatment of metastatic CRC is planned.


Colorectal cancer Tegafur UFT Oxaliplatin Metronomic chemotherapy 



This study was supported by grant VGH-92–254 from Taipei Veterans General Hospital and grant 94003 from Szu-Yuan Research Foundation, Taipei.


  1. 1.
    Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group New Engl J Med 343:905–914CrossRefGoogle Scholar
  2. 2.
    Tournigand C, Andre T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Onco 22:229–237CrossRefGoogle Scholar
  3. 3.
    de Gramont A, Vignoud J, Tournigand C et al (1997) Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-h continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33:214–219PubMedCrossRefGoogle Scholar
  4. 4.
    Andre T, Bensmaine MA, Louvet C et al (1999) Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 17:3560–3568PubMedGoogle Scholar
  5. 5.
    Maindrault-Goebel F, de Gramont A, Louvet C et al (2001) High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 37:1000–1005PubMedCrossRefGoogle Scholar
  6. 6.
    Hsieh RK, Chao TY, Chen WS et al (2004) Oxaliplatin added the simplified bimonthly low dose leucovorin and 5- FU on pretreated advanced colorectal cancer is effective and not affected by different previous 5-FU regimens. Cancer Invest 22:171–179PubMedCrossRefGoogle Scholar
  7. 7.
    Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30PubMedCrossRefGoogle Scholar
  8. 8.
    Ferrara N, Hillan KJ, Gerber HP et al (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391–400PubMedCrossRefGoogle Scholar
  9. 9.
    Browder T, Butterfield CE, Kraling BM et al (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878–1886PubMedGoogle Scholar
  10. 10.
    Klement G, Baruchel S, Rak J et al (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105:R15–R24PubMedGoogle Scholar
  11. 11.
    Hanahan D, Bergers G, Bergsland E et al (2000) Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105:1045–1047PubMedCrossRefGoogle Scholar
  12. 12.
    Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423–436PubMedCrossRefGoogle Scholar
  13. 13.
    Pietras K, Hanahan DA (2005) Multitargeted, metronomic, and maximum-tolerated dose “chemo-switch” regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23:939–952PubMedCrossRefGoogle Scholar
  14. 14.
    Miller KD, Sweeney CJ, Sledge GW et al (2005) Refining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 19:1195–1206Google Scholar
  15. 15.
    Yonekura K, Basaki Y, Chikahisa L et al (1999) UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. Clin Cancer Res 5:2185–2191PubMedGoogle Scholar
  16. 16.
    Tanaka F, Yanagihara K, Otake Y et al (2004) Angiogenesis and the efficacy of postoperative administration of UFT in pathologic stage I non-small cell lung cancer. Cancer Sci 95:371–376PubMedCrossRefGoogle Scholar
  17. 17.
    Rustum YM (1997) Mechanism-based improvement in the therapeutic selectivity of 5-FU prodrug alone and under conditions of metabolic modulation. Oncology (Karger) 1:7–11CrossRefGoogle Scholar
  18. 18.
    Maehara Y, Kakeji Y, Ohno S et al (1997) Scientific basis for the combination of tegafur with uracil. Oncology (Huntington) 11:14–21Google Scholar
  19. 19.
    Rougier P (1998) Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer. Semin Oncol 25:23–31PubMedGoogle Scholar
  20. 20.
    Carmichael J, Popiela T, Radstone D et al (2002) Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20:3617–3627PubMedCrossRefGoogle Scholar
  21. 21.
    Douillard JY, Hoff PM, Skillings JR et al (2002) Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20:3605–3616PubMedCrossRefGoogle Scholar
  22. 22.
    Saltz LB, Leichman CG, Young CW et al (1995) A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer. Cancer 75:782–785PubMedCrossRefGoogle Scholar
  23. 23.
    Maroun J, Asche C, Romeyer F et al (2003) A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada. Pharmacoeconomics 21:1039–1051PubMedCrossRefGoogle Scholar
  24. 24.
    Feliu J, Vicent JM, Garcia-Giron C et al (2004) Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer. Br J Cancer 91:1758–1762PubMedCrossRefGoogle Scholar
  25. 25.
    Kim K, Nam E, Lee NS et al (2002) Oxaliplatin and UFT combination chemotherapy in patients with metastatic colorectal cancer. Am J Clin Oncol 25:354–357PubMedCrossRefGoogle Scholar
  26. 26.
    Therasse P, Arbuck SG, Eisenheuer EA et al (2000) New Guide-lines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216PubMedCrossRefGoogle Scholar
  27. 27.
    Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10PubMedCrossRefGoogle Scholar
  28. 28.
    de Gramont A, Figer A, Seymour M et al ( 2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol.18:2938–2947Google Scholar
  29. 29.
    Reddy GK (2005) The addition of bevacizumab to FOLFOX4 prolongs survival in relapsed colorectal cancer: interim data from the ECOG 3200 trial. Clin Colorectal Cancer 4:300–301PubMedGoogle Scholar
  30. 30.
    Yoshikawa R, Kusunoki M, Yanagi H et al (2001) Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res 61:1029–1037PubMedGoogle Scholar
  31. 31.
    Borner MM, Schoffski P, de Wit R et al (2002) Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38:349–358PubMedCrossRefGoogle Scholar
  32. 32.
    Fischel JL, Formento P, Ciccolini J et al (2002) Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity. Br J Cancer 86:1162–1168PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Peng-Chan Lin
    • 1
    • 2
  • Wei-Shone Chen
    • 3
    • 4
  • Ta-Chung Chao
    • 1
  • Shung-Haur Yang
    • 4
  • Chui-Mei Tiu
    • 5
  • Jin-Hwang Liu
    • 1
    Email author
  1. 1.Division of Medical OncologyTaipei Veterans General Hospital and National Yang-Ming UniversityTaipeiTaiwan, ROC
  2. 2.Division of Hematology and Oncology, Department of Medicine, College of MedicineNational Cheng Kung University HospitalTainanTaiwan, ROC
  3. 3.Division of Experimental SurgeryTaipei Veterans General Hospital, School of Medicine National Yang-Ming UniversityTaipeiTaiwan, ROC
  4. 4.Division of Colorectal SurgeryTaipei Veterans General Hospital, School of Medicine National Yang-Ming UniversityTaipeiTaiwan, ROC
  5. 5.Department of RadiologyTaipei Veterans General Hospital, School of Medicine National Yang-Ming UniversityTaipeiTaiwan, ROC

Personalised recommendations